Paxalisib is under clinical development by Kazia Therapeutics and currently in Phase I for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis). According to GlobalData, Phase I drugs for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Paxalisib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Paxalisib overview
Paxalisib is under development for the treatment of high-grade glioblastoma or glioma, breast cancer metastases to brain, pediatric diffuse intrinsic pontine glioma, solid tumors with brain metastases and leptomeningeal metastases, primary CNS lymphoma and anaplastic astrocytoma, rhabdoid/teratoid tumors (AT/RT), focal cortical dysplasia type 2 (FCD T2) and tuberous sclerosis complex (TSC) disease, metastatic melanoma, triple-negative breast cancer, HER2 positive breast cancer and ovarian cancer. It is a small molecule administered oral route in the form of tablet or capsule. It acts by targeting the phosphoinositide 3-kinase and mTOR.
The drug candidate was under development for the treatment of patients recurrent high-grade glioblastoma or glioma.
Kazia Therapeutics overview
Kazia Therapeutics (Kazia) is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. The company’s product pipeline includes paxalisib (formerly GDC-0084), Cantrixil (TRX-E-002-1) and EVT801. Paxalisib is an inhibitor of PI3K /AKT /mTOR pathway to treat glioblastoma multiforme It is in phase II clinical trials. TRX-E-002-1 (Cantrixil) is a third generation benzopyran molecule that acts against cancer stem cells. Cantrixil is in phase I clinical trials for the treatment of ovarian cancer. EVT801 is a substance that blocks a cellular receptor called VEGFR3, which is responsible for the development of new blood and lymphatic vessels. The company has collaborations with various research institutes, hospitals, and universities including St Jude Children’s Hospital, University of Newcastle, Dana Farber Cancer Institute and Memorial Sloan Kettering Cancer Centre to develop its pipeline. Kazia is headquartered in Sydney, New South Wales, Australia.
For a complete picture of Paxalisib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.